Literature DB >> 34922758

Long-term assessment of efficacy with a novel Thoracic Survivorship Program for patients with lung cancer.

Hari B Keshava1, Kay See Tan2, Joe Dycoco1, James Huang1, Alison Berkowitz3, Dyana Sumner3, Amy Devigne3, Prasad Adusumilli1, Manjit Bains1, Matthew Bott1, James Isbell1, Robert Downey1, Daniela Molena1, Bernard Park2, Gaetano Rocco1, Smita Sihag1, David R Jones1, Valerie W Rusch4.   

Abstract

OBJECTIVE: We developed a novel, nurse practitioner-run Thoracic Survivorship Program to aid in long-term follow-up. Patients with non-small cell lung cancer who were disease-free at least 1 year after resection could be referred to the Thoracic Survivorship Program by their surgeon. Our objectives were to summarize follow-up compliance and assess long-term outcomes between Thoracic Survivorship Program enrollment and non-Thoracic Survivorship Program.
METHODS: Patients who underwent R0 resection for stages I to IIIA between 2006 and 2016 were stratified by enrollment in Thoracic Survivorship Program versus surgeon only follow-up (non-Thoracic Survivorship Program). Follow-up included 6-month chest computed tomography scans for 2 years and then annually. Lack of follow-up compliance was defined by 2 or more consecutive delayed annual computed tomography scans/visits ± 90 days. Relationships between Thoracic Survivorship Program and second primary non--small cell lung cancers, extrathoracic cancers, and survival were quantified using multivariable Cox proportional hazards regression with time-varying covariate reflecting timing of enrollment.
RESULTS: A total of 1162 of 3940 patients (29.5%) were enrolled in the Thoracic Survivorship Program. The median time to enrollment was 2.3 years; 3279 of 3940 (83%) had complete computed tomography scan data, and 60 of 3279 (1.8%) had 2 or more delayed scans; 323 of 9082 (3.6%) non-Thoracic Survivorship Program visits were noncompliant versus 132 of 4823 (2.7%) of Thoracic Survivorship Program visits (P = .009); 136 of 1146 Thoracic Survivorship Program patients developed second primary non-small cell lung cancer, and 69 of 1123 developed extrathoracic cancer, whereas 322 of 2794 of non-Thoracic Survivorship Program patients developed second primary non-small cell lung cancer and 225 of 2817 patients developed extrathoracic cancer. In multivariable analyses, Thoracic Survivorship Program enrollment was associated with improved disease-free survival (hazard ratio, 0.57; 95% confidence interval, 0.48-0.67; P < .001).
CONCLUSIONS: Our novel nurse practitioner-run Thoracic Survivorship Program is associated with high patient compliance and outcomes not different from those seen with physician-based follow-up. These results have important implications for health care resource allocation and costs.
Copyright © 2021 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  lung cancer follow-up; survivorship

Mesh:

Year:  2021        PMID: 34922758      PMCID: PMC9018489          DOI: 10.1016/j.jtcvs.2021.11.026

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   6.439


  25 in total

1.  Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach.

Authors:  Jason C Chang; Deepu Alex; Matthew Bott; Kay See Tan; Venkatraman Seshan; Andrew Golden; Jennifer L Sauter; Darren J Buonocore; Chad M Vanderbilt; Sounak Gupta; Patrice Desmeules; Francis M Bodd; Gregory J Riely; Valerie W Rusch; David R Jones; Maria E Arcila; William D Travis; Marc Ladanyi; Natasha Rekhtman
Journal:  Clin Cancer Res       Date:  2019-08-30       Impact factor: 12.531

2.  The rationale, design, and implementation of the American Cancer Society's studies of cancer survivors.

Authors:  Tenbroeck Smith; Kevin D Stein; C Christina Mehta; Chiewkwei Kaw; James L Kepner; Trent Buskirk; Jeremy Stafford; Frank Baker
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

3.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

4.  Explorations of lung cancer stigma for female long-term survivors.

Authors:  Cati Brown; Janine Cataldo
Journal:  Nurs Inq       Date:  2013-02-16       Impact factor: 2.393

5.  Implementing the commission on cancer standards for survivorship care plans.

Authors:  Carrie Tompkins Stricker; Michele O'Brien
Journal:  Clin J Oncol Nurs       Date:  2014       Impact factor: 1.027

6.  Accuracy of surveillance computed tomography in detecting recurrent or new primary lung cancer in patients with completely resected lung cancer.

Authors:  Robert J Korst; Amanda L Kansler; Jeffrey L Port; Paul C Lee; Nasser K Altorki
Journal:  Ann Thorac Surg       Date:  2006-09       Impact factor: 4.330

7.  Nurse specialist led follow-up in lung cancer: The experience of developing and delivering a new model of care.

Authors:  Sally Moore; Mary Wells; Hilary Plant; Frances Fuller; Majella Wright; Jessica Corner
Journal:  Eur J Oncol Nurs       Date:  2006-07-13       Impact factor: 2.398

8.  NCCN Guidelines Insights: Survivorship, Version 2.2020.

Authors:  Crystal S Denlinger; Tara Sanft; Javid J Moslehi; Linda Overholser; Saro Armenian; K Scott Baker; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Norah Lynn Henry; Christine Hill-Kayser; Melissa Hudson; Nazanin Khakpour; Divya Koura; Allison L McDonough; Michelle Melisko; Kathi Mooney; Halle C F Moore; Natalie Moryl; Tracey O'Connor; Electra D Paskett; Chirayu Patel; Lindsay Peterson; William Pirl; M Alma Rodriguez; Kathryn J Ruddy; Lillie Shockney; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Phyllis Zee; Nicole R McMillian; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2020-08       Impact factor: 11.908

9.  Incidence of local recurrence and second primary tumors in resected stage I lung cancer.

Authors:  N Martini; M S Bains; M E Burt; M F Zakowski; P McCormack; V W Rusch; R J Ginsberg
Journal:  J Thorac Cardiovasc Surg       Date:  1995-01       Impact factor: 5.209

10.  Oncologists' and primary care physicians' awareness of late and long-term effects of chemotherapy: implications for care of the growing population of survivors.

Authors:  Larissa Nekhlyudov; Noreen M Aziz; Catherine Lerro; Katherine S Virgo
Journal:  J Oncol Pract       Date:  2013-11-12       Impact factor: 3.840

View more
  3 in total

1.  Five decades of progress in surgical oncology: Tumors of the lung and esophagus.

Authors:  Valerie W Rusch
Journal:  J Surg Oncol       Date:  2022-10       Impact factor: 2.885

2.  Brief Report: Contralateral Lobectomy for Second Primary NSCLC: Perioperative and Long-Term Outcomes.

Authors:  Jennie K Choe; Amy Zhu; Alexander J Byun; Junting Zheng; Kay See Tan; Joe Dycoco; Manjit S Bains; Matthew J Bott; Robert J Downey; James Huang; James M Isbell; Daniela Molena; Valerie W Rusch; Bernard J Park; Gaetano Rocco; Smita Sihag; David R Jones; Prasad S Adusumilli
Journal:  JTO Clin Res Rep       Date:  2022-06-18

3.  Characterization and validation of a ferroptosis-related LncRNA signature as a novel prognostic model for lung adenocarcinoma in tumor microenvironment.

Authors:  Yuanyong Wang; Guofang Lu; Xinying Xue; Mei Xie; Zhaoyang Wang; Zhiqiang Ma; Yingtong Feng; Changjian Shao; Hongtao Duan; Minghong Pan; Peng Ding; Xiaofei Li; Jing Han; Xiaolong Yan
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.